ClinicalTrials.gg
Not yet recruitingNCT04598815SIRGOUpdated Mar 15, 2023

Sirolimus for Graves' Orbitopathy (GO)

A Phase 2 interventional study of Sirolimus in Graves Ophthalmopathy, sponsored by University of Pisa. Not yet recruiting at 1 site in Italy. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2023-03-15.

Sponsored by University of Pisa · Phase 2, Interventional, and Treatment

How we know

From the registry’s dates

  • Primary completion was expected by May 2024, 2 years 5 months ago, but the record still lists the study as not yet recruiting.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
54
Allocation
Randomized
Ages
18 Years to 75 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 11 studies in Graves Ophthalmopathy by University of Pisa — 4 open to participants now, 4 under way, 2 of them phase 3. Graves Ophthalmopathy · University of Pisa.

Started
2023
with 1 other
Phase 2
2 of 11
1 open now
Registered
8th of 11
by date

Among the 11 studies in Graves Ophthalmopathy by University of Pisa, this one is one of 2 that started in 2023, is one of 2 in phase 2, and was the 8th registered.

Graves Ophthalmopathy

200 studies on the registry are indexed under Graves Ophthalmopathy; 59 are open to participants now.

Browse Graves Ophthalmopathy studies →

Open to participants now

4 of the 11 studies in Graves Ophthalmopathy by University of Pisa are open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

All 4 open studies →

Where they have run

Who these studies take

Of the 39 Graves Ophthalmopathy studies recruiting now, 8 (21%) set no upper age limit and 17 (44%) stop at 75 or younger; 1 takes children under 18; 9 take healthy volunteers.

This study: 18 Years to 75 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 11 studies in Graves Ophthalmopathy by University of Pisa, or all of them as a file.
02

Study summary

Graves' Orbitopathy (GO) is a disabling and disfiguring condition associated with Graves' Disease, due to autoimmunity against antigens expressed by the thyroid and orbital tissues, and resulting in orbital fibroblast proliferation and release of glycosaminoglycans. The current treatments available, especially glucocorticoids, are not effective in all patients. Two cases of patients with GO treated with Sirolimus have been reported with an excellent response to the drug.

The rationale for the use of Sirolimus lies in its mechanisms of action. Sirolimus is able to inhibit T-cell activation as well as fibroblast proliferation. In addition, acts indirectly on the Insulin-Like Growth Factor-1 (IGF-1) pathway, and recent clinical trials have shown that a monoclonal antibody against the IGF-1 receptor (Teprotumumab) is effective in patients with GO. Thus, Sirolimus could be used in GO as monotherapy in patients with GO.

The aim of the present drug vs standard treatment, open-label, randomized clinical trial is to evaluate the efficacy of Sirolimus in patients with moderately severe, active GO.

54 patients (27 per group) will be randomized into two groups, A and B. Patients in group A will receive Sirolimus for 12 weeks. Patients in group B will receive methylprendnisolone for 12 weeks.

The primary objective of the study is the response of GO at 24 weeks based on a composite evaluation. The secondary Objectives will be: 1) the response of of GO at 12, 36 and 48 weeks; 2) Relapse of GO at 36 and 48 weeks (worsening compared with the 24-week evaluation); 3) The reduction of proptosis at 12, 24, 36 and 48 weeks (proportion of patients with a reduction of proptosis of at least 2 mm); 4) Reduction of the GO clinical activity score (CAS) at 12, 24, 36 and 48 weeks; 5) Quality of life (Qol) at 12, 24, 36 and 48 weeks.

The safety objectives will be adverse events, adverse drug reactions, unexpected adverse reaction, suspected unexpected adverse reactions and death, across the study and at 12, 24, 36 and 48 weeks.

Read the detailed description

Study Design Phase II, randomized, adaptive, superiority, open-label, single-center, pilot clinical trial.

Fifty-four patients with moderate-to-severe and active GO will be randomized into two intervention groups, A and B, with a ratio of 1: 1. Subjects assigned to group A will receive Sirolimus for 12 weeks. Patients assigned to group B will receive a cumulative dose of 4.5 g of methylprednisolone divided into 12 weekly infusions. This treatment scheme is the clinical standard and patients would be treated with methylprednisolone in any case, even if they did not accept to participate to the study.

Enrollment duration: 24 months Study duration: 36 months Tentative start of trial: July 1st 2022

Study Population Fifty-four patients with Graves' disease and GO will be recruited during the routine clinical activity carried out at the Endocrinology Unit II of AOUP, which is a tertiary referral center for thyroid diseases.

Study Timeline

  • Screening visit (2-6 weeks before the first visit)
  • 1st (baseline) visit - (Time 0): randomization and administration of the first dose of trial agent
  • Treatment period (week 1-week 12): daily administration of the trial agent (Sirolimus) or weekly administration of the standard treatment (methylprednisolone)
  • Methylprednisolone treatment period and treatment visits (week 2-week 13); weekly methylprednisolone administrations (week 2-week 13)
  • Safety visits (week 3, 5, 7, 9, 11)
  • 2nd visit (week 12)
  • 3rd visit (week 24)
  • 4th visit (week 36)
  • 5th visit (week 48)
03

Conditions studied

  • Graves Ophthalmopathy

Browse trials for

04

Who can participate

Ages eligible
18 Years to 75 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Patients willing and capable of giving written , which includes compliance with the requirements and restrictions listed in the consent form
  2. A diagnosis of Graves' disease based on the presence of hyperthyroidism (either untreated or treated with antithyroid drugs) associated with detectable anti-thyrotropic hormone (TSH) receptor autoantibodies (TRAb). Patients must be euthyroid under control on stable medical regimen and every effort will be made to maintain the euthyroid status for the entire duration of the clinical trial
  3. A moderate-to-severe GO, defined as the presence of at least one of the following criteria: an exophthalmos ≥2 mm compared with normal values for sex and race; presence of inconstant to constant diplopia; a lid retraction ≥2 mm
  4. Active GO: CAS (4) ≥2 out of 7 points in the most affected eye
  5. GO duration ≤18 months
  6. Male and female patients of age: 18-75 years
  7. Creatinine values within the reference range
  8. Indexes of liver function (, ALT, γGT, alkaline phosphatase, total and direct ) within the normal range
  9. Normal blood count, absence of diseases of hematopoiesis
  10. Women of (WOCBP, namely not in menopause or in menopause since less than two years; in all other instances women will be considered as non-WOCBP) and men who are sexually active with WOCBP must use any method with a failure rate of less than 1% per year (as indicated in Appendix) for at least 6 and 7,5 months, respectively, after the last dose of the drug (see also 2014_09_HMA_CTFG_Contraception.pdf, namely the "2014 CTFG Reccommendtions related to contraception and pregnancy testing in clinical trials")
  11. Compliant patients, regular follow-up possible

Exclusion criteria

Exclusion Criteria:

  1. Optic neuropathy
  2. Treatment with , other drugs or selenium for the last three months
  3. Previous surgery or radiotherapy for GO
  4. Radioiodine treatment for hyperthyroidism over the last 3 months, as it can affect GO
  5. to Sirolimus: to the active substance or to any of the ; use of medications interfering with the pharmacokinetic and/or pharmacodynamic properties of rapamycin (e.g. inhibitors or inducers; see "prohibited therapies")
  6. Contraindications to GC: hypersensitivity to the active substance or to any of the excipients; uncontrolled hypertension, uncontrolled diabetes; history of peptic ulcer; urinary infections, glaucoma, systemic fungal infections, systemic infections unless appropriate therapy is employed, idiopathic thrombocytopenic purpura, cerebral edema associated with malaria.
  7. Use of medications interfering with GC or increasing the risk of GC-related adverse events (see prohibited therapies)
  8. Pregnant or lactating females as determined by positive serum or urine HCG test at baseline
  9. Acute or chronic liver disease
  10. Relevant
  11. Current and/or previous diseases of hematopoiesis
  12. Recent (≤1 year) history of alcoholism or drug abuse
  13. Mental illness that prevent patients from comprehensive, written
Terms in these criteria, in plain language(13)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

CYP3A (CYP3A4) inhibitors and inducers

CYP3A is a group of enzymes, mainly CYP3A4, in the liver and gut that break down many medicines. Some medicines, supplements and foods (grapefruit, St John’s wort) slow them down or speed them up, which changes how much of a study drug stays in the body.

Studies list them so they can be avoided or switched; bring a list of everything you take, including supplements.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
54 participants (estimated)

Study arms

  • Experimental
    Sirolimus

    Sirolimus for 12 weeks

    Drug: Sirolimus

  • Experimental
    Methylprendnisolone

    Methylprednisolone for 12 weeks

    Drug: Sirolimus

Interventions

  • Group Sirolimus: Patients will receive a first dose of Sirolimus of one 2 mg tablet on the first day, given approximately at 10 am, followed by 0.5 mg tablet per day for 12 weeks. Group Methylprednisolone: Methylprednisolone pulse therapy will be administered for 12 weeks as follows: 500 mg iv once weekly for 6 weeks, then 250 mg iv once weekly for a further 6 weeks, for a cumulative dose 4.5 g.

    Also known as: Rapamycin

06

What researchers measure

Primary outcomes

  1. GO overall response

    Percentage of subjects with at least two of the following compared to baseline: a) Improvement in CAS by at least 1 point ; b) Improvement in exophthalmos by at least 2 mm; c) Improvement in lid aperture by at least 2 mm; d) Improvement in eye muscle ductions ≥8 degrees; e) Improvement of visual acuity by at least 0.2/1, without worsening of any of these parameters in the contralateral eye if applicable.

    Time frame: 24 weeks

Secondary outcomes

  1. GO overall response

    Percentage of subjects with at least two of the following compared to baseline: a) Improvement in CAS by at least 1 point ; b) Improvement in exophthalmos by at least 2 mm; c) Improvement in lid aperture by at least 2 mm; d) Improvement in eye muscle ductions ≥8 degrees; e) Improvement of visual acuity by at least 0.2/1, without worsening of any of these parameters in the contralateral eye if applicable.

    Time frame: 12 weeks

  2. GO overall response

    Percentage of subjects with at least two of the following compared to baseline: a) Improvement in CAS by at least 1 point ; b) Improvement in exophthalmos by at least 2 mm; c) Improvement in lid aperture by at least 2 mm; d) Improvement in eye muscle ductions ≥8 degrees; e) Improvement of visual acuity by at least 0.2/1, without worsening of any of these parameters in the contralateral eye if applicable.

    Time frame: 36 weeks

  3. GO overall response

    Percentage of subjects with at least two of the following compared to baseline: a) Improvement in CAS by at least 1 point ; b) Improvement in exophthalmos by at least 2 mm; c) Improvement in lid aperture by at least 2 mm; d) Improvement in eye muscle ductions ≥8 degrees; e) Improvement of visual acuity by at least 0.2/1, without worsening of any of these parameters in the contralateral eye if applicable.

    Time frame: 48 weeks

  4. GO relapse

    Percentage of subjects with worsening of GO in comparison with the 24 week evaluation. Worsening is defined as change in two of the following in at least one eye (compared to baseline): a) Worsening in CAS by at least 1 point; b) Worsening of exophthalmos (\>2 mm); c) Worsening of lid aperture (\>2 mm); d) Worsening of eye ductions ≥8 degrees; d) Worsening of visual acuity by at least 0.2/1

    Time frame: 36 weeks

  5. GO relapse

    Percentage of subjects with worsening of GO in comparison with the 24 week evaluation. Worsening is defined as change in two of the following in at least one eye (compared to baseline): a) Worsening in CAS by at least 1 point; b) Worsening of exophthalmos (\>2 mm); c) Worsening of lid aperture (\>2 mm); d) Worsening of eye ductions ≥8 degrees; d) Worsening of visual acuity by at least 0.2/1

    Time frame: 48 weeks

  6. Change in exophthalmos

    Percentage of subjects with a reduction greater than or equal to 2 mm compared with the baseline evaluation in the study eye, without worsening in the contralateral eye

    Time frame: 12 weeks

  7. Change in exophthalmos

    Percentage of subjects with a reduction greater than or equal to 2 mm compared with the baseline evaluation in the study eye, without worsening in the contralateral eye

    Time frame: 24 weeks

  8. Change in exophthalmos

    Percentage of subjects with a reduction greater than or equal to 2 mm compared with the baseline evaluation in the study eye, without worsening in the contralateral eye

    Time frame: 36 weeks

  9. Change in exophthalmos

    Percentage of subjects with a reduction greater than or equal to 2 mm compared with the baseline evaluation in the study eye, without worsening in the contralateral eye

    Time frame: 48 weeks

  10. Change in the clinical activity score (CAS)

    Percentage of subjects with a reduction of CAS by at least two points in the study eye, without worsening in the contralateral eye

    Time frame: 12 weeks

  11. Change in the clinical activity score (CAS)

    Percentage of subjects with a reduction of CAS by at least two points in the study eye, without worsening in the contralateral eye

    Time frame: 24 weeks

  12. Change in the clinical activity score (CAS)

    Percentage of subjects with a reduction of CAS by at least two points in the study eye, without worsening in the contralateral eye

    Time frame: 36 weeks

  13. Change in the clinical activity score (CAS)

    Percentage of subjects with a reduction of CAS by at least two points in the study eye, without worsening in the contralateral eye

    Time frame: 48 weeks

  14. Change in quality of life

    Comparison of the quality of life scores between the two groups, determined with a questionnaire specific for GO (GO-QoL)

    Time frame: 12 weeks

  15. Change in quality of life

    Comparison of the quality of life scores between the two groups, determined with a questionnaire specific for GO (GO-QoL)

    Time frame: 24 weeks

  16. Change in quality of life

    Comparison of the quality of life scores between the two groups, determined with a questionnaire specific for GO (GO-QoL)

    Time frame: 36 weeks

  17. Change in quality of life

    Comparison of the quality of life scores between the two groups, determined with a questionnaire specific for GO (GO-QoL)

    Time frame: 48 weeks

  18. Percentage of adverse events

    Percentage of adverse events, adverse drug reactions, death across the study period

    Time frame: 48 weeks

07

Study locations

1 site
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Start is estimated for Jun 2023; primary completion for May 2024, 11 months later.

How these figures are worked out, and which studies are left out of them.

Registered
Oct 16, 2020
First posted
Oct 22, 2020
StartEst.
Jun 1, 2023
Primary completionEst.
May 31, 2024
CompletionEst.
May 31, 2025
Last update
Mar 15, 2023
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Mar 15, 2023, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT04598815
Lead sponsor
University of Pisa
Responsible party
Marinò Michele (Associate Professor, University of Pisa) — Principal investigator
First posted
Oct 22, 2020
Start date
Jun 1, 2023 (estimated)
Primary completion
May 31, 2024 (estimated)
Completion
May 31, 2025 (estimated)
Last update
Mar 15, 2023

Study contacts

Michele Marinò, MD
Contact
michele.marino@med.unipi.it
+39050997346
Giulia Lanzolla, MD
Contact
giulia.lanzolla8@gmail.com
+393407685085

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Mar 2023. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Sirolimus

Start the discussion